Eagle Capital Growth Fund Inc (GRF) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a...

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of...

Form DEF 14A - Other definitive proxy statements

Form N-CSR - Certified Shareholder Report

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Grifols announces positive topline phase 3 fibrinogen clinical trial results

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 5 - Annual statement of changes in beneficial ownership of securities

Form 40-17G - Fidelity Bond [Rule 17G-1(g)]

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an...

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)